Federated Hermes’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Federated Hermes’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-28,582	Closed	-$104K	–	2346
2021 Q4	$104K	Buy	+28,582	New	+$153K	﹤0.01%	1706
2018 Q3	–	Sell	-6	Closed	-$1K	–	2342
2018 Q2	$1K	Sell	6 -10	-63%	-$890	﹤0.01%	2166
2018 Q1	$2K	Buy	+16	New	+$2.74K	﹤0.01%	2073
2017 Q1	–	Sell	-3,143	Closed	-$398K	–	2197
2016 Q4	$398K	Hold	3,143	–	–	﹤0.01%	1373
2016 Q3	$481K	Buy	3,143 +1,238	+65%	+$175K	﹤0.01%	1299
2016 Q2	$219K	Hold	1,905	–	–	﹤0.01%	1471
2016 Q1	$216K	Hold	1,905	–	–	﹤0.01%	1480
2015 Q4	$359K	Hold	1,905	–	–	﹤0.01%	1376
2015 Q3	$324K	Hold	1,905	–	–	﹤0.01%	1402
2015 Q2	$1.2M	Buy	1,905 +476	+33%	+$253K	﹤0.01%	1094
2015 Q1	$735K	Buy	1,429 +477	+50%	+$241K	﹤0.01%	1265
2014 Q4	$510K	Sell	952 -148	-13%	-$66.7K	﹤0.01%	1346
2014 Q3	$1.65M	Sell	1,100 -380	-26%	-$550K	0.01%	1035
2014 Q2	$2.03M	Sell	1,480 -782	-35%	-$907K	0.01%	944
2014 Q1	$3.14M	Buy	+2,262	New	+$2.63M	0.01%	787

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Federated Hermes's VIRX Position: Q1 2022 in Review

Federated Hermes sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2022, closing a stake of 28,582 shares — an estimated $104K sold.

Federated Hermes first reported a position in VIRX in Q1 2014 and held it in 15 quarters. The position peaked at $3.14M in Q1 2014. 69 funds tracked by Wall St. Rank hold VIRX as of Q1 2022.

Federated Hermes reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Federated Hermes sold 28,582 Viracta Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $104K.
Federated Hermes first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 15 quarters.
Federated Hermes's Viracta Therapeutics, Inc. Common Stock position peaked at $3.14M in Q1 2014.
69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Federated Hermes's 13F filing for Q1 2022, filed 13 May 2022.